Raymond James Financial Services Advisors Inc. Has $545,000 Stock Holdings in Amarin Co. plc (NASDAQ:AMRN)

Raymond James Financial Services Advisors Inc. cut its position in Amarin Co. plc (NASDAQ:AMRN) by 3.5% during the 4th quarter, HoldingsChannel reports. The firm owned 626,346 shares of the biopharmaceutical company’s stock after selling 22,806 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Amarin were worth $545,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AMRN. Creative Planning raised its holdings in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 6,900 shares during the period. MML Investors Services LLC grew its position in shares of Amarin by 129.1% in the 3rd quarter. MML Investors Services LLC now owns 27,721 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 15,620 shares during the period. Quantbot Technologies LP bought a new position in shares of Amarin in the 1st quarter valued at about $31,000. Sei Investments Co. bought a new position in shares of Amarin in the 4th quarter valued at about $33,000. Finally, GTS Securities LLC bought a new position in shares of Amarin in the 2nd quarter valued at about $35,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $1.08.

Amarin Stock Performance

Shares of AMRN stock opened at $0.87 on Friday. The company has a market capitalization of $358.02 million, a price-to-earnings ratio of -6.23 and a beta of 1.98. The company has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $0.93. Amarin Co. plc has a 52 week low of $0.65 and a 52 week high of $1.49.

Amarin (NASDAQ:AMRN) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The business had revenue of $74.71 million during the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. Sell-side analysts forecast that Amarin Co. plc will post -0.14 EPS for the current year.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.